Success will look like a health ecosystem that can develop biomedical innovation, and also adopt it rapidly and consistently.  We are committed to working with UK Government and the NHS to make this vision a reality.  

Although the NHS is rightly a source of great national pride, UK health outcomes continue to lag behind 9 of 11 similar countries in terms of chronic disease and overall mortality; mortality preventable by timely and effective health care; and disease-specific outcomes such as death rates following stroke, heart attack and survival after a cancer diagnosis)[1]. Link to:  Mirror, Mirror 2017: International Comparison Reflects Flaws and Opportunities for Better U.S. Health Care 

Improved productivity, efficiency and NHS transformation are essential to improve these statistics. However, a solution that allows NHS funding to increase sustainably is also needed.  The UK currently spends just 9.9% of Gross Domestic Product on healthcare, sixth out of the G7 nations, with only Italy spending less2 Link to : ONS Digital, ‘How does UK healthcare spending compare internationally’, 2016. It also invests a relatively low share of healthcare spend on medicines. As a result, patients in the UK are still often unable to access cost-effective new treatments, and the health of population as a whole fails to improve as much as it could.  The Competitiveness Indicators published by the Office of Life Sciences show that, on average, for every 100 patients in comparable countries who get access to a new medicine in its first year of launch, just 18 patients in the UK receive the same3Life Sciences Competitive Indicators, Office for Life Sciences, April 2017That’s not compatible with the vision of a world class health system.

The ABPI is working with the NHS and government to find ways to increase health and care investment to the G7 average and ensure that the UK is in the top quartile of comparable countries for patient access to new cost-effective medicines and vaccines by 2022. 

Key to this will be a streamlined, NICE-led, system for the assessment of medicines in England, integrated into a new, voluntary PPRS. A new system should be evidence based, reduce duplication and recognise the wide-ranging benefits that new medicines bring to the lives of patients and the NHS.

We believe that interconnected health and care data is also critical to delivering the vision of a world-class service by 2030.  The data potential of the NHS as a single health system providing universal coverage is the single most powerful asset for the UK in attracting life sciences investment. Working with the Academic Health Science Network, our members are contributing to building the data capability of the NHS to expand registries, connect data sets and correlate health interventions with population outcomes.

We’re helping to implement the UK Life Sciences Industrial Strategy (link) and the work of the Accelerated Access Collaborative (link). Our goal is to cement the UK’s position as a leading global hub for the life science industry, attracting significant new international investment and giving NHS patients the fastest possible access to new, more cost-effective treatments.